Trial · NCT07895355
Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer
NCT07895355, Phase 2, Not yet recruiting, RemeGen Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer. Trials, record NCT07895355. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895355
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer
- NCT number
- NCT07895355
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 412 participants, estimated
- Lead sponsor
- RemeGen Co., Ltd.
- Conditions
- Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy
- Interventions
RC148 plus Telisotuzumab adizutecan, RC148 plus Telisotuzumab adizutecan, RC148 plus Telisotuzumab adizutecan, RC148 plus Telisotuzumab adizutecan, Telisotuzumab adizutecan plus Bevacizumab, Telisotuzumab adizutecan plus Bevacizumab
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ORR as assessed by the Investigator per RECIST v1.1 | From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months | |
| Primary | The incidence and severity of AEs, vital signs, physical examinations, ECGs, and laboratory test | Screening through 120 days after the last dose of RC148/telisotuzumab adizutecan/bevacizumab or 28 days after the last dose of 5-FU/LV, whichever is late | |
| Secondary | RC148 and Telisotuzumab adizutecan concentrations at each time-point post-dosing | 24 months | |
| Secondary | Maximum concentration (Cmax) of RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | Time to Cmax (Tmax) of RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | Area under the concentration-time curve for a dosing interval (AUCtau) of RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | Area under the concentration-time curve extrapolated to infinity (AUCinf) of RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | Elimination half-life (t1/2) of RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | Incidence of ADA for RC148 and Telisotuzumab adizutecan | 24 months | |
| Secondary | Onset timing of ADA for RC148 and Telisotuzumab adizutecan | 24 months |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895355
GET https://conductscience.org/api/trials/v1/NCT07895355/registered